Form 8-K - Current report:
SEC Accession No. 0001193125-23-132621
Filing Date
2023-05-02
Accepted
2023-05-02 17:01:03
Documents
13
Period of Report
2023-05-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d851586d8k.htm   iXBRL 8-K 29819
2 EX-99.1 d851586dex991.htm EX-99.1 16694
  Complete submission text file 0001193125-23-132621.txt   179332

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bmea-20230501.xsd EX-101.SCH 2865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bmea-20230501_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bmea-20230501_pre.xml EX-101.PRE 11717
7 EXTRACTED XBRL INSTANCE DOCUMENT d851586d8k_htm.xml XML 3461
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 23880207
SIC: 2834 Pharmaceutical Preparations